UK's Omicron Specific Boosters Are Already Ineffective, But NHS Will Push Them Anyway

Moderna’s upcoming “bivalent” inoculation booster is targeting not one but two prior (and thus no longer circulating) strains of the SARS-CoV-2 virus. Unsurprisingly, it is already shown to have less impact against the current strains of the virus. The UK’s NHS wants it anyway, because reasons.

Moderna's bivalent booster — along with a similar one made by Pfizer and BioNTech — is more effective against the newer variants of the virus than the original vaccines are.

But these bivalent shots were designed around the original omicron variant, and as a result, they're less effective against BA.4 and BA.5.

Despite all the initial grandiose posturing by Big Pharma, their mRNA inoculations are not only toxic and dangerous, but they cannot be rolled out fast enough to keep pace with the ongoing evolution of the SARS-CoV-2 virus. Even the effective license to cut corners implied by the reliance on Emergency Use Authorization has not enabled them to move fast enough to get ahead of the virus.

The virus is going to continue to virus, and Big Pharma is going to continue to be two steps behind.